Works matching IS 00071048 AND DT 2017 AND VI 176 AND IP 5

Results: 21
    1
    2
    3
    4
    5

    The future of academic haematology.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 5, p. 721, doi. 10.1111/bjh.14472
    By:
    • Hay, Deborah;
    • Hatton, Christian S.R.;
    • Weatherall, David J.
    Publication type:
    Article
    6

    Exacerbation of oxidative stress during sickle vaso-occlusive crisis is associated with decreased anti-band 3 autoantibodies rate and increased red blood cell-derived microparticle level: a prospective study.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 5, p. 805, doi. 10.1111/bjh.14476
    By:
    • Hierso, Régine;
    • Lemonne, Nathalie;
    • Villaescusa, Rinaldo;
    • Lalanne‐Mistrih, Marie‐Laure;
    • Charlot, Keyne;
    • Etienne‐Julan, Maryse;
    • Tressières, Benoit;
    • Lamarre, Yann;
    • Tarer, Vanessa;
    • Garnier, Yohann;
    • Hernandez, Ada Arce;
    • Ferracci, Serge;
    • Connes, Philippe;
    • Romana, Marc;
    • Hardy‐Dessources, Marie‐Dominique
    Publication type:
    Article
    7

    The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 5, p. 750, doi. 10.1111/bjh.14477
    By:
    • Chihara, Dai;
    • Fanale, Michelle A.;
    • Miranda, Roberto N.;
    • Noorani, Mansoor;
    • Westin, Jason R.;
    • Nastoupil, Loretta J.;
    • Hagemeister, Fredrick B.;
    • Fayad, Luis E.;
    • Romaguera, Jorge E.;
    • Samaniego, Felipe;
    • Turturro, Francesco;
    • Lee, Hun J.;
    • Neelapu, Sattva S.;
    • Rodriguez, M. Alma;
    • Wang, Michael;
    • Fowler, Nathan H.;
    • Davis, Richard E.;
    • Medeiros, L. Jeffrey;
    • Hosing, Chitra;
    • Nieto, Yago L.
    Publication type:
    Article
    8

    Issue Information.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 5, p. 675, doi. 10.1111/bjh.14352
    Publication type:
    Article
    9
    10
    11
    12
    13

    Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 5, p. 743, doi. 10.1111/bjh.14465
    By:
    • Lu, Jin;
    • Lee, Jae H.;
    • Huang, Shang‐Yi;
    • Qiu, Lugui;
    • Lee, Je‐Jung;
    • Liu, Ting;
    • Yoon, Sung‐Soo;
    • Kim, Kihyun;
    • Shen, Zhi X.;
    • Eom, Hyeon S.;
    • Chen, Wen M.;
    • Min, Chang K.;
    • Kim, Hyo J.;
    • Lee, Jeong O.;
    • Kwak, Jae Y.;
    • Yiu, Wai;
    • Chen, Guang;
    • Ervin‐Haynes, Annette;
    • Hulin, Cyrille;
    • Facon, Thierry
    Publication type:
    Article
    14
    15

    RB but not R- HCVAD is a feasible induction regimen prior to auto- HCT in frontline MCL: results of SWOG Study S1106.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 5, p. 759, doi. 10.1111/bjh.14480
    By:
    • Chen, Robert W.;
    • Li, Hongli;
    • Bernstein, Steven H.;
    • Kahwash, Samir;
    • Rimsza, Lisa M.;
    • Forman, Stephen J.;
    • Constine, Louis;
    • Shea, Thomas C.;
    • Cashen, Amanda F.;
    • Blum, Kristie A.;
    • Fenske, Timothy S.;
    • Barr, Paul M.;
    • Phillips, Tycel;
    • Leblanc, Michael;
    • Fisher, Richard I.;
    • Cheson, Bruce D.;
    • Smith, Sonali M.;
    • Faham, Malek;
    • Wilkins, Jennifer;
    • Leonard, John P.
    Publication type:
    Article
    16

    Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2<sup>nd</sup>-line therapy for relapsed and refractory multiple myeloma - a phase II trial.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 5, p. 770, doi. 10.1111/bjh.14481
    By:
    • Mey, Ulrich J. M.;
    • Brugger, Wolfram;
    • Schwarb, Heike;
    • Pederiva, Stefanie;
    • Schwarzer, Andreas;
    • Dechow, Tobias;
    • Jehner, Paul;
    • Rauh, Jacqueline;
    • Taverna, Christian J.;
    • Schmid, Mathias;
    • Schmidt‐Hieber, Martin;
    • Doerfel, Steffen;
    • Fischer, Natalie;
    • Ruefer, Axel;
    • Ziske, Carsten;
    • Knauf, Wolfgang;
    • Cathomas, Richard;
    • Moos, Roger;
    • Hitz, Felicitas;
    • Sauter, Rafael
    Publication type:
    Article
    17

    Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 5, p. 783, doi. 10.1111/bjh.14483
    By:
    • Raje, Noopur S.;
    • Moreau, Philippe;
    • Terpos, Evangelos;
    • Benboubker, Lotfi;
    • Grząśko, Norbert;
    • Holstein, Sarah A.;
    • Oriol, Albert;
    • Huang, Shang‐Yi;
    • Beksac, Meral;
    • Kuliczkowski, Kazimierz;
    • Tai, Datchen F.;
    • Wooldridge, James E.;
    • Conti, Ilaria;
    • Kaiser, Christopher J.;
    • Nguyen, Tuan S.;
    • Cronier, Damien M.;
    • Palumbo, Antonio
    Publication type:
    Article
    18
    19
    20
    21